{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Salt+Water&page=9",
    "query": {
      "intervention": "Salt Water",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 273,
    "total_pages": 28,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Salt+Water&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Salt+Water&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T19:56:06.310Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01073930",
      "title": "Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bowel Preparation"
      ],
      "interventions": [
        {
          "name": "PicoPrep",
          "type": "DRUG"
        },
        {
          "name": "HalfLytely",
          "type": "DRUG"
        },
        {
          "name": "bisacodyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 608,
      "start_date": "2010-05",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2013-02-12",
      "last_synced_at": "2026-10-30T19:56:06.310Z",
      "location_count": 9,
      "location_summary": "Huntsville, Alabama • Sherwood, Arkansas • Bristol, Connecticut + 6 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Sherwood",
          "state": "Arkansas"
        },
        {
          "city": "Bristol",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01073930"
    },
    {
      "nct_id": "NCT03055195",
      "title": "Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Mepolizumab 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching mepolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 34,
      "start_date": "2017-03-21",
      "completion_date": "2017-12-06",
      "has_results": true,
      "last_update_posted_date": "2020-02-25",
      "last_synced_at": "2026-10-30T19:56:06.310Z",
      "location_count": 11,
      "location_summary": "Fort Smith, Arkansas • Fremont, California • Santa Ana, California + 8 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Sandy Springs",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03055195"
    },
    {
      "nct_id": "NCT03461211",
      "title": "Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Teprotumumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2018-04-16",
      "completion_date": "2021-02-17",
      "has_results": true,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-10-30T19:56:06.310Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03461211"
    },
    {
      "nct_id": "NCT02061800",
      "title": "CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia (CML)",
        "Acute Myelogenous Leukemia (AML)",
        "Myelodysplastic Syndrome (MDS)",
        "Juvenile Myelomonocytic Leukemia (JMML)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Lymphoma (Hodgkin's and Non-Hodgkin's)"
      ],
      "interventions": [
        {
          "name": "CliniMACS CD34+ Reagent System",
          "type": "DEVICE"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Diane George",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "Up to 22 Years"
      },
      "enrollment_count": 14,
      "start_date": "2013-06-03",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2024-06-04",
      "last_synced_at": "2026-10-30T19:56:06.310Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02061800"
    },
    {
      "nct_id": "NCT03794102",
      "title": "Water Versus Saline as Irrigation Fluid for Ureteroscopy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ureteral Stricture",
        "Hydronephrosis",
        "Urothelial Carcinoma",
        "Urolithiasis"
      ],
      "interventions": [
        {
          "name": "Water",
          "type": "OTHER"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2017-01-17",
      "completion_date": "2018-06-30",
      "has_results": false,
      "last_update_posted_date": "2019-01-04",
      "last_synced_at": "2026-10-30T19:56:06.310Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03794102"
    },
    {
      "nct_id": "NCT05997264",
      "title": "Anthrax AV7909 Boost Evaluation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "AV7909 Full Dose (0.5 mL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AV7909 Half Dose (0.25 mL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 220,
      "start_date": "2023-12-05",
      "completion_date": "2026-08-19",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-30T19:56:06.310Z",
      "location_count": 7,
      "location_summary": "Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more",
      "locations": [
        {
          "city": "Hickory",
          "state": "North Carolina"
        },
        {
          "city": "Salisbury",
          "state": "North Carolina"
        },
        {
          "city": "Statesville",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Jefferson City",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05997264"
    },
    {
      "nct_id": "NCT00801931",
      "title": "Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Neuroblastoma",
        "Immunodeficiencies",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Phenytoin",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Horse Antithymocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "Rabbit Antithymocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 1,
      "start_date": "2007-09-06",
      "completion_date": "2009-05-05",
      "has_results": true,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-10-30T19:56:06.310Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00801931"
    },
    {
      "nct_id": "NCT05346302",
      "title": "Persistent Readiness Through Early Prediction Immunization Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Inflammatory Response"
      ],
      "interventions": [
        {
          "name": "Pneumovax 23",
          "type": "DRUG"
        },
        {
          "name": "Typhim VI",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Texas A&M University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 249,
      "start_date": "2022-02-08",
      "completion_date": "2022-12-21",
      "has_results": false,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-10-30T19:56:06.310Z",
      "location_count": 1,
      "location_summary": "College Station, Texas",
      "locations": [
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05346302"
    },
    {
      "nct_id": "NCT01672710",
      "title": "Gulf War Illness: Evaluation of an Innovative Detoxification Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gulf War Illness"
      ],
      "interventions": [
        {
          "name": "plain crystalline niacin, exercise, sauna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University at Albany",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 32,
      "start_date": "2010-04",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2020-04-13",
      "last_synced_at": "2026-10-30T19:56:06.310Z",
      "location_count": 1,
      "location_summary": "Annapolis, Maryland",
      "locations": [
        {
          "city": "Annapolis",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01672710"
    },
    {
      "nct_id": "NCT01250496",
      "title": "Study With Aminophylline to Attenuate of the Side Effects of Regadenoson",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan"
      ],
      "interventions": [
        {
          "name": "Aminophylline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 248,
      "start_date": "2010-11",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2023-03-13",
      "last_synced_at": "2026-10-30T19:56:06.310Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250496"
    }
  ]
}